Remodulin — Total revenues
United Therapeutics Remodulin — Total revenues decreased by 1.1% to $126.60M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 8.4%, from $138.20M to $126.60M. Over 4 years (FY 2021 to FY 2025), Remodulin — Total revenues shows relatively stable performance with a 0.6% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase suggests successful market penetration or growth in patient adoption, while a decrease may indicate increased competition, patent expiration, or loss of market share.
Detailed definition
Represents the total gross or net sales generated from a specific pharmaceutical product or therapeutic line. This metri...
Peer comparison
Commonly reported as 'Product Revenue' or 'Net Sales' by pharmaceutical and biotech companies for individual key assets.
uthr_segment_remodulin_total_revenuesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $139.80M | $125.40M | $118.30M | $131.70M | $132.00M | $114.00M | $122.50M | $121.40M | $127.20M | $131.10M | $115.10M | $128.00M | $147.30M | $128.30M | $134.50M | $138.20M | $134.70M | $125.90M | $128.00M | $126.60M |
| QoQ Change | — | -10.3% | -5.7% | +11.3% | +0.2% | -13.6% | +7.5% | -0.9% | +4.8% | +3.1% | -12.2% | +11.2% | +15.1% | -12.9% | +4.8% | +2.8% | -2.5% | -6.5% | +1.7% | -1.1% |
| YoY Change | — | — | — | — | -5.6% | -9.1% | +3.6% | -7.8% | -3.6% | +15.0% | -6.0% | +5.4% | +15.8% | -2.1% | +16.9% | +8.0% | -8.6% | -1.9% | -4.8% | -8.4% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is United Therapeutics's remodulin — total revenues?
- United Therapeutics (UTHR) reported remodulin — total revenues of $126.60M in Q1 2026.
- How has United Therapeutics's remodulin — total revenues changed year-over-year?
- United Therapeutics's remodulin — total revenues decreased by 8.4% year-over-year, from $138.20M to $126.60M.
- What is the long-term trend for United Therapeutics's remodulin — total revenues?
- Over 4 years (2021 to 2025), United Therapeutics's remodulin — total revenues has grown at a 0.6% compound annual growth rate (CAGR), from $513.70M to $526.80M.
- What does remodulin — total revenues mean?
- The total amount of money earned from sales of a specific drug product.